229 patents
Page 5 of 12
Utility
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
5 Jul 22
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Xingxing Zang
Filed: 20 Dec 19
Utility
Reversibly Switchable Photoacoustic Imaging Systems and Methods
9 Jun 22
Reversibly switchable photoacoustic tomography (RS-PAT), a photoacoustic technique with enhanced sensitivity and resolution, is disclosed.
Vladislav V. Verkhusha, Andrii A. Kaberniuk, Lihong Wang, Junjie Yao, Lei Li
Filed: 10 Nov 21
Utility
31387ujhnl9bv3xw lb7vts
7 Jun 22
Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof.
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Filed: 9 May 17
Utility
y78rx7wcpvjls58se41mggl8zrfvvbupd089rrqbguoblp
26 May 22
Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.
Betsy C. HEROLD, Garnett KELSOE, Masayuki KURAOKA, Clare BURN, William R. Jacobs, Jr.
Filed: 19 Mar 20
Utility
58awkd8ww nkkux98jfvvmcxrea91gap5kj7xndlbe26p16k9wz
24 May 22
The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides.
Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel, III
Filed: 17 May 17
Utility
y5v4u4pnop yfuaqa19ssddyihqpxl
12 May 22
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 26 Jan 22
Utility
a0zerhcuu8jmyzf0si2qo1omt2 gfz1fvmnw
12 May 22
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 30 Dec 21
Utility
ta0b6vx3c5kf 3xq98uvatb
28 Apr 22
Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
Claudia Gravekamp
Filed: 16 Nov 21
Utility
2x8w0rqdutc6qq4ggs3dd3b57svn zntw5h5nugu46d64dupd3rfysib
31 Mar 22
The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A).
Carl ERICKSON, Christopher P. RUSCONI, Matthew LEVY, Keith E. MAIER, Sarah E. THACKER, Derek PARKS
Filed: 10 Jan 20
Utility
yu6yt7gbmrokyb0hk t12p10zo71cgmw8kwucq2k8dlvdhsiqg
31 Mar 22
Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof.
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Filed: 3 May 21
Utility
a4618u3pnbpq7jrbfq0gwwe9v2pcuyetfg
24 Mar 22
Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.
Betsy HEROLD, William JACOBS, JR., Pablo A. GONZALEZ-MUNOZ, Christopher PETRO
Filed: 3 Jan 20
Utility
jj03p3qtusknl1ju4ulf7ftdmmnbgov5eeffwmb3 0er
24 Mar 22
A genetically modified mammalian cell and genetically modified mammalian cell line comprise a recombination sequence inserted in a target locus on a chromosome of the mammalian cell genome, wherein the recombination sequence comprises Bxb1attB sequence from Mycobacterium smegmatis.
William R. Jacobs, Jr., Lawrence Leung, Regy Lukose, Anna Paula de Oliveira
Filed: 24 Sep 21
Utility
oic9jhty exdtr5pdxzfms5hv
22 Mar 22
Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses.
Steven C. Almo, Tyler Grove, Anthony Gizzi, Craig E. Cameron, James J. Arnold
Filed: 21 Aug 18
Utility
1g5vn1da5n5jlk3xdja 4usmp8qk0
17 Mar 22
Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.
Sridhar Mani, Libusha Kelly, Hao Li
Filed: 8 Oct 21
Utility
ozcb8z05opwz1rmx3wu6h50uci
1 Mar 22
Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
Xingxing Zang
Filed: 5 Sep 18
Utility
8iv1ihiyfe06g5sn39h4o2nlbsrzqrv7
22 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
0qoszp5nwj63t5mn79116nyo wt1hdmsrzhe
17 Feb 22
Disclosed are human Programmed Cell Death-1 (PD-1) receptor mutants having selectivity for PD-L1 compared to PD-L2, methods of obtaining the mutants, and uses of the mutants for treatment and imaging.
Andras Fiser, Rojan Shrestha, Steven C. Almo, Sarah, C. Garrett
Filed: 18 Sep 19
Utility
nafd6w4lzw3vcfpzm8s1tyiy3ph4j6v3439lg6
8 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
cgxr6 i35i211sqb6rs9rlf5jai0r
8 Feb 22
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection.
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Filed: 9 Jun 20
Utility
pxtr6m6iqkiwtzsg2p5rsyyhh1lw3apb34da 97aybgg3pdwvmtr6q
27 Jan 22
Provided herein are small molecule compounds and methods inhibiting human sulfotransferase 1A3 (SULT1A3) using these small molecule compounds.
Alexander Deiters, Kristie E. Darrah, Mary Frances Cacace, Ian Cook, Thomas Leyh, Ting Wang
Filed: 10 Dec 19